<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81600">
  <stage>Registered</stage>
  <submitdate>14/09/2006</submitdate>
  <approvaldate>15/09/2006</approvaldate>
  <actrnumber>ACTRN12606000405516</actrnumber>
  <trial_identification>
    <studytitle>Atorvastatin for Renal Protection After Cardiopulmonary Bypass</studytitle>
    <scientifictitle>A phase II randomised, double-blind, placebo-controlled study of the effect of atorvastatin on postoperative renal function in patients undergoing elective cardiopulmonary bypass</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Acute kidney injury</healthcondition>
    <healthcondition>Cardiac surgery with cardiopulmonary bypass</healthcondition>
  </conditions>
  <interventions>
    <interventions>atorvastatin 40mg orally starting morning of surgery pre-pump and the same dose continued daily orally for 3 days post-operatively</interventions>
    <comparator>Identical placebo orally starting morning of surgery pre-pump and the same dose continued daily orally for 3 days post-operatively</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute kidney injury as measured by change in serum creatinine</outcome>
      <timepoint> 72 hours post-operative.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic markers of oxidative stress and inflammation, drug toxicity, adverse events, length of stay, need for renal replacement therapy, death.</outcome>
      <timepoint>72 hours post-operative and at any time during the period of hospitalization.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Informed consent2. Elective cardiac surgery in males/females3. Planned cardiopulmonary bypass4. &gt;1 risk factors for post-operative renal dysfunction.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Emergent cardiac surgery, cardiac transplant or insertion of device2. Planned off-pump cardiac surgery3. Hypersensitivity, allergy or known intolerance to statins4. Pre-morbid end-stage kidney disease or renal transplant5. Pre-operative ARF, defined as an increase in serum creatinine Â³88.4mmol/L (1.0mg/dL) from pre-admission to operation6. Active liver disease or cirrhosis7. Pre-operative unexplained elevation of serum transaminases8. Enrolled in a conflicting study9. Pregnancy10. Age below 18 years11. Pre-operative acute inflammation (e.g. endocarditis)12. Moderate to high-dose steroid therapy (e.g. &gt;10mg prednisone or equivalent per day).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation by central randomization by phone/fax through the hospital pharmacy.</concealment>
    <sequence>Stratified allocation by pre-operative statin therapy, randomization by randomization table from a statistics book</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Patient, clinician, surgeon, investigator and data-analysis will be blinded to allocation</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/12/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>102</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Hospital, Department of Intensive Care</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Austin Anaesthesia and Intensive Care Trust</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Rinaldo Bellomo</name>
      <address>Department of Intensive Care,
Austin Hospital
Heidelberg, VIC</address>
      <phone>03-9496-5992</phone>
      <fax>03-9496-3992</fax>
      <email>rinaldo.bellomo@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Sean M Bagshaw</name>
      <address>Department of Intensive Care,
Austin Hospital
Heidelberg, VIC</address>
      <phone>03-9496-3801</phone>
      <fax>03-9496-3992</fax>
      <email>sean.bagshaw@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>